Why Life Sciences localization grew 147% in six months and what it means for your vendor selection

AI Overview

The 147% surge in life sciences translation over the past six months is a structural shift, and if you’re responsible for vendor selection, it’s a warning signal.

This spike, highlighted in The State of Language Operations Outsourcing 2025/2026 Report, wasn’t driven by more content in the traditional sense. It came from compliance pressure. Specifically, regulatory frameworks like IVDR, MDR, and the continued expansion of software as a medical device (SaMD) requirements have fundamentally changed what “done” looks like in Life Sciences localization.

For procurement teams, that means one thing: the vendor criteria that worked even 12-18 months ago are no longer sufficient.

This article breaks down what actually changed and how to adjust your medical translation vendor selection process before those gaps show up in an audit.

The 147% growth is a compliance signal 

At first glance, a 147% increase in life sciences translation volume looks like a scaling problem. More markets, more content, more languages. That’s the familiar story. But that’s not what the data shows.

The growth is tied directly to regulatory expansion, particularly IVDR/MDR localization requirements in Europe and parallel compliance pressures across Asian markets. The increase isn’t coming from marketing content or IFU updates alone. It’s coming from:

• Reclassification of medical devices under stricter frameworks
• Expanded documentation requirements per product
• Mandatory multilingual submissions across a broader set of jurisdictions
• Ongoing updates to previously approved materials

In other words, the same product now generates significantly more regulated content and that content must meet stricter standards across more languages. For vendor managers, this changes the procurement question entirely. It’s no longer:

“Can this vendor handle our volume?”

It’s:

“Can this vendor handle regulated content at scale without introducing compliance risk?”

That’s a very different evaluation.

Why standard TEP production is no longer enough

Most vendor selection frameworks in life sciences localization still assume a TEP model (translation, editing, proofreading) is sufficient. For general content, it often is. For regulated content under IVDR and MDR, it isn’t. The gap comes down to accountability and traceability.

In a standard TEP workflow:

• Linguists work sequentially
• Edits are accepted or rejected with limited arbitration
• Terminology may be applied, but not actively governed
• Responsibility is distributed, not owned

That model breaks under compliance pressure.

Regulated content requires:

1. Linguistic Sign-Off (LSO)
   A named, accountable expert who owns the final output, not just contributes to it.
2. In-Country Review (ICR) arbitration
   Structured resolution of reviewer feedback, not informal comment handling.
3. Subject-matter accountability
   Linguists who are not just native speakers, but domain-qualified in medical, clinical, or regulatory content.
4. Terminology governance
   Centralized control of approved terms, enforced consistently across languages and updates.

Without these elements, TEP becomes a production process rather than a compliance process. And that distinction is exactly where most vendor evaluation frameworks fall short.

The hidden weakness in most vendor selection models

If you look at how most LSPs approach vendor selection, the criteria haven’t materially changed in years:

• ISO certifications
• Turnaround time
• Cost per word
• Language coverage
• Capacity claims

These are necessary, but they’re no longer sufficient. That gap is especially risky in Asian language production, where:

• Reviewer layers are often more complex
• Regulatory expectations vary significantly by market
• Terminology standardization is harder to enforce
• Linguist pools with true subject-matter expertise are limited

In practice, many vendors that “pass” traditional evaluation frameworks are still operating with production models that cannot support compliance-grade life sciences translation. The result?

Issues remain undetected during the onboarding phase. They show up during submission or worse, during audit.

Why Asian language production is the stress test

The State of Language Operations Outsourcing 2025/2026 Report makes one thing clear: Asian languages are where these weaknesses become visible fastest. Not because vendors are weaker but because the requirements are stricter in practice. Consider what happens in a typical regulated workflow involving Japanese, Korean, or Simplified Chinese:

• Multiple in-country stakeholders review the same content
• Feedback is often subjective, conflicting, or regulator-influenced
• Timelines are compressed due to submission dependencies
• Updates must be propagated across versions with full traceability

In a standard TEP model, this creates friction. In a compliance-grade model, it requires infrastructure:

• Defined arbitration workflows
• Version-controlled terminology systems
• Clear ownership of final linguistic decisions
• Documented audit trails

Most vendor selection frameworks don’t test for any of this. Which means procurement teams are often approving vendors based on inputs (certifications, rates) rather than outputs (compliance-ready deliverables).

What changed in the last six months

Three shifts matter most:

1. Volume is now tied to regulation, not expansion

This is mandatory output tied to compliance frameworks. That means failure becomes a regulatory risk.

2. Quality is now defined by defensibility

“High quality” used to mean linguistically accurate and stylistically consistent. Now it means:

• Traceable decisions
• Justified terminology
• Documented reviewer resolution

3. Vendor capability is now about systems, not just people

Strong linguists are still essential, but without the right process infrastructure, even excellent linguists cannot deliver compliance-grade outcomes consistently. This is the shift most procurement frameworks haven’t caught up with.

Updating your medical translation vendor selection approach

If your current medical translation vendor selection process still prioritizes cost, speed, and certifications, you’re not alone. But you are exposed. The practical move now is to update how you evaluate partners, especially for regulated Asian language work.

That starts with asking better questions. Not generic capability questions. Operational, testable, compliance-focused questions.

The five questions you should now be asking any vendor

These questions are designed to surface whether a vendor operates at a production level or at a compliance level.

1. How do you implement linguistic sign-off (LSO) for regulated content?

What to listen for:

• Named individuals responsible for final approval
• Clear criteria for sign-off
• Separation between production and accountability

Red flag:
“Final review is done by the proofreader” or “the client approves everything.”

2. What is your process for ICR arbitration when reviewers disagree?

What to listen for:

• Structured arbitration workflows
• Defined roles in decision-making
• Documentation of final decisions

Red flag:
“We consolidate comments and send them back to the linguist.”

3. How do you enforce terminology governance across languages and updates?

What to listen for:

• Centralized termbases
• Approval workflows for new terms
• Version control across projects

Red flag:
“Terminology is managed per project” or “we rely on glossaries provided by the client.”

4. How do you ensure subject-matter accountability in your linguist pool?

What to listen for:

• Domain-specific qualification criteria
• Ongoing evaluation tied to medical content

Red flag:
“All linguists are native and experienced” (without domain specificity).

5. What audit trail can you provide for a completed project?

What to listen for:

• Traceable changes across versions
• Logged reviewer decisions
• Documented sign-off and approvals

Red flag:
“We can provide final files and tracked changes if needed.”

What this means for your next vendor review cycle

You don’t need to panic but you do need to adjust. The key takeaway from the 147% growth in life sciences localization is simple: The risk has shifted upstream. Vendor capability is now not only about delivering translations but about enabling compliance outcomes.

And that means your evaluation framework has to evolve to “Can they defend what they produce?”, which is a higher bar, but now the relevant one.